Fennec Pharmaceuticals Inc.: CMO Sayad Sargis received 3,846 shares

What happened The Form 4 reports that Sayad Pierre Sargis, chief medical officer, acquired 3,846 common shares at $5.53 per share on Oct 12, 2026, for a total of $21,268. The transaction is recorded as an award/grant or other acquisition (code A).

Key details

• Transaction date and price: Oct 12, 2026 at $5.53 per share.
• Total shares acquired and value: 3,846 shares for $21,268.
• Shares owned after the transaction: not reported in the filing.
• Relevant footnotes: F1 — shares were acquired pursuant to the Fennec Pharmaceuticals Inc. Employee Stock Purchase Plan (ESPP) for the purchase period Apr 9, 2026 through Oct 12, 2026; F2 — shares were purchased based on 85% of the closing price on Apr 9, 2026.
• Transaction code: A (grant/award/other acquisition).
• Filing timeliness: not marked late in the filing.

Why it may matter

• The shares were acquired through the company ESPP rather than an open-market purchase.
• This filing does not show why the insider traded or why the company acted.